TransMedics Group (TMDX) & Its Rivals Critical Comparison

TransMedics Group (NASDAQ:TMDX – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its competitors? We will compare TransMedics Group to related businesses based on the strength of its analyst recommendations, dividends, risk, earnings, institutional ownership, profitability and valuation.

Institutional & Insider Ownership

99.7% of TransMedics Group shares are held by institutional investors. Comparatively, 40.6% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Comparatively, 15.0% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk & Volatility

TransMedics Group has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Comparatively, TransMedics Group’s competitors have a beta of 2.68, suggesting that their average share price is 168% more volatile than the S&P 500.

Profitability

This table compares TransMedics Group and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
TransMedics Group 19.85% 13.30% 4.93%
TransMedics Group Competitors -300.70% -179.63% -22.71%

Valuation & Earnings

This table compares TransMedics Group and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
TransMedics Group $605.49 million $190.29 million 25.44
TransMedics Group Competitors $1.90 billion $137.78 million 5.72

TransMedics Group’s competitors have higher revenue, but lower earnings than TransMedics Group. TransMedics Group is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for TransMedics Group and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TransMedics Group 0 7 5 0 2.42
TransMedics Group Competitors 4314 10603 18404 838 2.46

TransMedics Group currently has a consensus price target of $113.30, indicating a potential upside of 20.70%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 23.31%. Given TransMedics Group’s competitors stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group has less favorable growth aspects than its competitors.

Summary

TransMedics Group competitors beat TransMedics Group on 7 of the 13 factors compared.

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc. is a medical technology company focused on improving organ transplantation. Its Organ Care System (OCS) is a portable platform that perfuses donor organs with warm, oxygenated blood and nutrients while they are outside the body. The company offers OCS systems for donor hearts, lungs and livers, along with related consumables and services. The company also operates the National OCS Program in the United States, an integrated offering that combines its technology with organ procurement and transportation services.

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.